TABLE 2.
OGTT-derived indexes of glucose homeostasis in patients with biopsy-proven NAFLD and controls, grouped according to TM6SF2 rs58542926 C/T genotype (n = 120)
| TM6SF2 C/T Genotype | ||||||
| Controls | NAFLD | |||||
| CC (n = 40) | CT/TT (n = 20) | P | CC (n = 40) | CT/TT (n = 20) | P | |
| OGIS (ml min−1 m−2) | 427.9 ± 13.5 | 442.6 ± 15.1 | 0.318 | 385.5 ± 7.4a | 392.2 ± 11.0a | 0.810 |
| Hepatic IR (g/dl glucose·μU/mlIns·min−2) | 2,615.7 ± 126.4 | 3,298.4 ± 173.5 | 0.001 | 4,180.1 ± 107.4a | 4,779.7 ± 182.1b | 0.002 |
| Muscle IS | 0.014 ± 0.002 | 0.021 ± 0.001 | 0.028 | 0.012 ± 0.001 | 0.018 ± 0.002 | 0.002 |
| Adipose IR (mmol/l/pmol/l) | 21.2 ± 2.0 | 30.1 ± 1.4 | 0.0004 | 48.6 ± 4.2b | 88.4 ± 6.8b | 0.0001 |
| Hepatic extraction (%) | 74 ± 3 | 72 ± 4 | 0.414 | 73 ± 5 | 69 ± 7 | 0.582 |
| IGI (μUinsulin g−1glucose) | 187 ± 11 | 112 ± 14 | 0.009 | 171 ± 19c | 106 ± 13b | 0.001 |
| CGI (ngC-pep g −1glucose) | 511 ± 12 | 401 ± 11 | 0.0009 | 502 ± 13c | 394 ± 16b | 0.001 |
| DI (μUinsulin g−1glucose ml−1 m−2) | 80,124 ± 4,318 | 48,615 ± 4,379 | 0.001 | 52,136 ± 3,615c | 37,639 ± 1,713b | 0.0001 |
| AI (ngC-pep g−1glucose ml-1 m−2) | 220,709 ± 12,138 | 175,241 ± 8,136 | 0.009 | 189,420 ± 8,372c | 142,671 ± 9,139b | 0.001 |
| Incretin effect (%) | 72.6 ± 3.2 | 47.3 ± 2.9 | 0.0002 | 70.9 ± 3.1 | 45.2 ± 4.1 | 0.0001 |
Data are presented as mean ± SEM, unless otherwise specified. Statistically significant P values are in bold. IS, insulin sensitivity.
a
P < 0.05 versus controls.
b
P < 0.01 versus. controls.
c
P < 0.05 versus controls bearing the same genotype.